Paper Details

  1. Home
  2. Paper Details

Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy.

Author: AntellMartine H, BourqueBrian, DiloretoStefanie, HeoSuyeon, RotoloShannon M, SafirsteinJulie, YoungDavid C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Elexacaftor/tezacaftor/ivacaftor (Trikafta) is a new drug for Cystic Fibrosis. There are no documented reports of mental status changes with this drug, however, 6 patients reported 'mental fogginess' or other mental status changes shortly after initiating this drug. The mechanism of this patient-reported side effect is still unclear.
Paper Details　
Original Abstract of the Article :
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta) is the newest Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drug approved by the Food and Drug Administration. Post-marketing reports with earlier CFTR modulators suggest these medications can impact mood, and in clinica...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jcf.2021.10.002

データ提供：米国国立医学図書館（NLM）

Exploring Mental Status Changes with Trikafta

This case series examines a fascinating phenomenon in the realm of cystic fibrosis (CF) treatment. It explores the potential impact of the new CFTR modulator drug, elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta), on mental status. This research is like venturing into a newly discovered oasis, seeking to understand the effects of a powerful new medicine on the human mind. The study focuses on six patients who reported experiencing 'mental fogginess' after starting Trikafta, highlighting the need for further investigation into the potential neurological side effects of this promising drug.

Mental Fogginess: A Potential Side Effect of Trikafta

The study reports that all six patients experienced mental fogginess or other mental status changes within the first three months of Trikafta treatment. While the exact mechanism of this side effect remains unclear, this observation emphasizes the need for careful monitoring and patient-centered decision-making during Trikafta treatment. It's like navigating a desert landscape where the unexpected can arise, and vigilance is key to ensuring a safe journey.

Addressing Mental Status Changes During Trikafta Therapy

The researchers highlight the importance of personalized care for patients on Trikafta. It's crucial to be attentive to any changes in mental status, discuss concerns openly, and collaborate with CF care teams to find the best approach for each patient. It's like having a skilled guide who helps you navigate the challenging terrain of a new medication.

Dr. Camel's Conclusion

This study underscores the importance of ongoing research and vigilant monitoring in the realm of CF treatment. As we explore new therapeutic horizons, understanding the nuances of these powerful medications is essential to ensuring the well-being of our patients. It's like having a skilled guide who helps you navigate the challenging terrain of a new medication.

Date :
  1. Date Completed 2022-04-13
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

34742667

DOI: Digital Object Identifier

10.1016/j.jcf.2021.10.002

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.